
Unicycive Therapeutics: FDA Accepts OLC NDA; Q3 Cash $59M
Unicycive Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for oxylanthanum carbonate (OLC), setting a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027. The company also reported its financial results for the third quarter ended September 30, 2026, with cash, cash equivalents, and marketable securities totaling $59 million, providing runway beyond 2027. R&D expenses decreased year-over-year, while G&A expenses increased due to commercial launch preparations. The net loss for the quarter widened slightly.
Key Highlights
- Unicycive Therapeutics announces FDA acceptance of NDA resubmission for oxylanthanum carbonate (OLC) with a PDUFA date of March 25, 2027.
- As of September 30, 2026, the company had $59 million in cash, cash equivalents, and marketable securities, with runway expected beyond 2027.
- Research and Development (R&D) expense decreased to $2.2 million for Q3 2026 from $3.0 million in Q3 2025.
- General and Administrative (G&A) expense increased to $6.6 million for Q3 2026 from $4.4 million in Q3 2025, driven by commercial launch preparation.
- Net loss attributable to common stockholders was $(7.0) million, or $(0.25) per share, for Q3 2026, compared to $(6.0) million, or $(0.33) per share, for Q3 2025.
Price Impact
More from UNCY
Unicycive Therapeutics Appoints New Director; Resubmits NDA for Oxylanthanum Carbonate
Unicycive Q2 Net Loss $(1.7)M; FDA Assigns OLC Facility Inspection
Unicycive: FDA Inspection Assigned for OLC; Cash $61.4M